Lupus & antiphospholipid syndrome
Low serum lipocalin-2 in pregnant women with systemic lupus erythematosus
Authors' conclusion
In a population of SLE women with low disease activity we have not found evidence that serum LCN2 levels predict disease activity or adverse pregnancy outcomes.
Study context
- Population
- Pregnant women with systemic lupus erythematosus (SLE) (quiescent disease), rheumatoid arthritis (RA) and healthy pregnancies; serum sampled preconception, each trimester, and 6 weeks, 6 months and 12 months postpartum
- Participants
- 25 / 27 / 18
- Exposure
- SLE pregnancies vs RA and healthy pregnancies
- SLEn = 25
- RAn = 27
- Healthyn = 18reference
- Outcome
- Serum LCN2 levels
Methodological detailsseven sampling time points (preconception to 12 months postpartum), t-test at each time point, linear mixed effects model
- Seven sampling time points (preconception to 12 months postpartum)
- T-test at each time point
- Linear mixed effects model
Main finding
As reported in the abstract
Serum LCN2 levels throughout pregnancy
- Significantly lower serum LCN2 throughout pregnancy in SLE with quiescent disease vs RA and healthy pregnancies
Observational data: associations, not effects.
Further findings
Association of serum LCN2 with disease activity or adverse pregnancy outcome in SLE
- No association found
Original publication
Low serum lipocalin-2 in pregnant women with systemic lupus erythematosus. Clin Exp Rheumatol. Published 11 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →